Aptorum Group Limited (APM)
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference
📈 **POSITIVE** • Medium confidence analysis (74%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical